PeproMene Bio Highlights Significant Advances in Cancer Therapy
IRVINE, Calif. — PeproMene Bio, Inc. is making waves in the biotechnology sector with its innovative developments in CAR T cell therapies aimed at treating relapsed and refractory (r/r) B-cell malignancies. The company has recently announced that two abstracts from the ongoing Phase 1 studies of its leading therapy, PMB-CT01 (BAFFR-CAR T), have been accepted for oral presentations. These presentations will occur at an upcoming prestigious annual meeting.
Key Highlights of PMB-CT01 Research
These abstracts reveal a promising exploration into the safety and efficacy of PMB-CT01, particularly for patients suffering from heavily pretreated forms of B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL). Notably, the studies focus on individuals who have previously failed CD19-directed therapies or present with CD19-negative disease.
Interim findings from the Phase 1 dose-escalation studies support the BAFF-R target as a differentiated approach that effectively addresses the challenge of CD19 antigen escape. This positions PMB-CT01 as not only safe but also as a therapy maintaining durable activity with low toxicity profiles.
Results in r/r B-NHL
When examining the results within the r/r B-NHL patient group, PMB-CT01 demonstrated a remarkably favorable side effect profile. Notably, there were no instances of Grade ?1 Cytokine Release Syndrome (CRS) and no serious cases of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS).
In terms of efficacy, all the first seven patients treated achieved a Complete Response (CR) within a timeframe of 1 to 3 months post-infusion. This achievement included patients who had undergone prior CD19 CAR T therapy, as well as those with CD19-negative disease. The durability of these remissions is impressive, with some ongoing for over 32 months and a median duration of 17 months at the data cutoff.
Insights from r/r B-ALL
In another cohort focusing on r/r B-ALL, four out of six enrolled patients achieved an undetectable Minimal Residual Disease (MRD-) Complete Remission (CR). Significantly, three of the four responders were identified as CD19-negative at the start of their treatment. Remarkably, all three successfully transitioned to allogeneic hematopoietic cell transplant with a goal of achieving a cure.
Safety remained paramount, with no Dose-Limiting Toxicities (DLTs) observed. While one patient experienced Grade 2 CRS, it was reassuring that there were no reported cases of Grade 3 CRS.
Expert Commentary on Findings
Dr. Hazel Cheng, COO of PeproMene Bio, noted, "The consistent and durable efficacy observed across both B-ALL and B-NHL patient groups, especially among those who have exhausted previous treatment options, underscores BAFF-R as a compelling and safe alternative target. These results highlight PMB-CT01's crucial potential in meeting significant unmet needs in this high-risk population."
Details of ASH 2025 Oral Presentations
The two oral presentations will be key moments for PeproMene Bio at ASH 2025:
- Abstract Title: BAFFR-CAR T cells demonstrate durable responses and manageable toxicities in r/r B-cell lymphomas…
- Abstract: abs25-7079
Date/Time: December 6, 2:45 PM
Presenter: Elizabeth Budde, M.D., Ph.D.
- Abstract Title: BAFFR-CAR T cells show promising safety and anti-leukemia efficacy in r/r B-cell ALL patients…
- Abstract: abs25-2035
Date/Time: December 8, 11:00 AM
Presenter: Ibrahim Aldoss, M.D.
These presentations are anticipated to generate significant interest, showcasing the groundbreaking work being conducted at PeproMene Bio.
About PMB-CT01
PMB-CT01 is a pioneering BAFF-R–targeted autologous CAR T cell therapy that is specifically designed to engage B cells, an essential component for achieving success in treating B-cell malignancies. The therapy is currently under active evaluation in Phase 1 trials targeting r/r B-NHL and r/r B-ALL.
Frequently Asked Questions
What is PMB-CT01?
PMB-CT01 is an innovative BAFF-R–targeted autologous CAR T cell therapy for treating B-cell malignancies.
What type of patients have been studied?
Patients with heavily pretreated r/r B-ALL and r/r B-NHL, including some who have failed previous therapies, were studied.
What were the safety findings from the studies?
The studies reported no significant severe adverse events such as Grade ?1 CRS or ICANS in early subjects.
What efficacy outcomes did the trials report?
The trials reported a high complete response rate among participants, showcasing the therapy's potential effectiveness.
When are the oral presentations scheduled?
The oral presentations are scheduled for December 6 and December 8 at the ASH 2025 meeting.
